查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1433604

大麻藥品市場規模、佔有率、趨勢分析報告：按品牌類型、地區、細分市場預測，2024-2030 年

Cannabis Pharmaceuticals Market Size, Share & Trends Analysis Report By Brand Type (Sativex, Epidiolex, Other Brands), By Region (North America, Europe, Asia Pacific), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

大麻藥品市場成長與趨勢：

Grand View Research, Inc. 的最新報告顯示，到 2030 年，全球大麻藥品市場預計將達到 115.3 億美元。

預計2024年至2030年該市場將以32.6%的複合年成長率擴張。大麻擴大用於治療睡眠障礙、疼痛、發炎、癲癇、思覺失調症各種適應症，正在推動市場成長。對用於醫療目的的加工、量化和包裝大麻產品的需求正在顯著增加。此外，消費者和監管機構對大麻產品的接受程度正在提高，這對市場成長產生了積極影響。例如，監管機構對 Epidiolex 和 Sativex 等大麻產品的核准正在改善患者和醫生對大麻使用的觀點。

不斷增加的研發活動和產品核可預計將在預測期內推動市場成長。例如，2021年8月，GW Pharmaceuticals獲得英國藥品和保健品監管局（MHRA）的核准，使用EPIDYOLEX治療結節性硬化症發作。據估計，此類核准將增加製藥業對大麻的需求。

越來越多的臨床試驗證明利用大麻藥物治療多發性硬化症、癲癇、慢性疼痛和癌症等各種疾病的積極作用正在推動市場的成長，這是主要的促進因素。臨床試驗產生的積極結果可以幫助改變患者和醫療保健專業人員看待大麻和使用大麻開發的藥物的方式。例如，根據 ClinicalTrials.gov 提供的資料，截至 2022 年，約有 722 項 Sativex 試驗正在進行中，或正在招募、不再招募或透過邀請入組。

大麻藥品市場報告亮點

  • 以品牌類型分類， 磊晶細分市場在2023年佔據全球市場最大的銷售佔有率，達98.5%。該領域的成長得益於各國核准用於治療嚴重癲癇、Dravet 症候群、 腸漏症候群和結節性硬化症的進展。
  • 由於醫用大麻使用者數量不斷增加以及該地區主要製造商的存在，歐洲在 2023 年佔據了最大的收益佔有率。
  • 預計拉丁美洲市場在預測期內將以最快的速度成長。這是由於該地區大麻藥物合法化的擴大和使用大麻藥物的有利指導方針。

目錄

第1章 大麻藥品市場：調查方法與範圍

第2章大麻藥品市場：執行摘要

  • 市場展望
  • 分部展望
  • 競爭考察

第3章 大麻藥品市場：變數、趨勢、範圍

  • 市場體系展望
  • 市場動態
  • 大麻藥品市場分析工具

第4章 大麻藥品市場：依品牌類型的估計和趨勢分析

  • 依品牌類型分類的市場佔有率(2023/2030)
  • 細分儀表板
  • 按品牌類型分類的市場前景
  • 市場規模、預測與趨勢分析（2018-2030）

第5章 大麻藥品市場：按地區估計和趨勢分析

  • 按地區分類的市場佔有率分析（2023/2030）
  • 按地區分類的市場儀表板
  • 按地區分類的市場概況
  • 市場規模、預測與趨勢分析（2018-2030）
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 瑞士
    • 捷克共和國
    • 克羅埃西亞
    • 波蘭
    • 荷蘭
  • 亞太地區
    • 日本
    • 澳洲
    • 韓國
    • 紐西蘭
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 烏拉圭
    • 智利
    • 秘魯
  • 中東/非洲
    • 以色列

第6章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商形勢
    • Jazz Pharmaceuticals, Inc.
    • AbbVie, Inc.
    • Insys Therapeutics, Inc.
    • Bausch Health Companies, Inc.
Product Code: GVR-4-68038-473-4

Cannabis Pharmaceuticals Market Growth & Trends:

The global cannabis pharmaceutical market size is expected to reach USD 11.53 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 32.6% from 2024 to 2030.The rise in applications of cannabis for various indications, including sleep disorders, pain, inflammation, epilepsy, anorexia, multiple sclerosis, and schizophrenia, is driving the market growth. Demand for processed, quantified, and packaged cannabis products for medical purposes is significantly increasing. Moreover, consumer and regulatory acceptance of cannabis products is increasing, positively impacting the market growth. For instance, regulatory approval of cannabis-based products such as Epidiolex and Sativex is improving the perspectives of both patients and physicians regarding the use of cannabis.

An increasing number of research and development activities and product approvals are anticipated to drive market growth over the forecast period. For instance, in August 2021, GW Pharmaceutical received approval for using EPIDYOLEX to treat tuberous sclerosis complex seizures from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). Such approvals are estimated to increase demand for cannabis in the pharmaceutical industry.

The rising number of clinical trials signifying the positive effects of utilizing cannabis pharmaceuticals for treating various medical conditions, such as multiple sclerosis, epilepsy, chronic pain, and cancer, is a major factor boosting market growth. Positive results provided by clinical trials help to change the perspective of patients & healthcare professionals toward cannabis and pharmaceutical drugs developed using cannabis. For instance, as per the data provided by ClinicalTrials.gov, as of 2022, there are around 722 studies for Sativex that are active, either recruiting, not recruiting, or enrolling by invitation.

Cannabis Pharmaceuticals Market Report Highlights:

  • By brand type, epidiolex segment held the largest revenue share of 98.5% in the global market in 2023. Growing approval of the drug for the treatment of severe forms of epilepsy, Dravet syndrome, Lennox Gastaut syndrome, and Tuberous Sclerosis Complex in various countries is supporting segment growth
  • Europe accounted for the largest revenue share in 2023, owing to growing number of medical cannabis users, along with the presence of major manufacturers in the region
  • Latin American markets are estimated to grow at the fastest rate during the forecast period. This can be attributed to growing legalization and favorable guidelines toward using cannabis pharmaceuticals in the region

Table of Contents

Chapter 1. Cannabis Pharmaceuticals Market: Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Brand Type
    • 1.2.2. Regional scope
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Cannabis Pharmaceuticals Market: Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Brand type outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Cannabis Pharmaceuticals Market: Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Cannabis Pharmaceuticals Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Cannabis Pharmaceuticals Market: Brand Type Estimates & Trend Analysis

  • 4.1. Brand Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Cannabis Pharmaceuticals Market by Brand Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Sativex
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Epidiolex
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Other Brands
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Cannabis Pharmaceuticals Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2023 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Global Regional Market Snapshot
  • 5.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 5.5. North America
    • 5.5.1. U.S.
      • 5.5.1.1. Key country dynamics
      • 5.5.1.2. Regulatory framework
      • 5.5.1.3. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. Canada
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Regulatory framework
      • 5.5.2.3. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Europe
    • 5.6.1. UK
      • 5.6.1.1. Key country dynamics
      • 5.6.1.2. Regulatory framework
      • 5.6.1.3. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.2. Germany
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Regulatory framework
      • 5.6.2.3. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.3. France
      • 5.6.3.1. Key country dynamics
      • 5.6.3.2. Regulatory framework
      • 5.6.3.3. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.4. Italy
      • 5.6.4.1. Key country dynamics
      • 5.6.4.2. Regulatory framework
      • 5.6.4.3. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.5. Switzerland
      • 5.6.5.1. Key country dynamics
      • 5.6.5.2. Regulatory framework
      • 5.6.5.3. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.6. Czech Republic
      • 5.6.6.1. Key country dynamics
      • 5.6.6.2. Regulatory framework
      • 5.6.6.3. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.7. Croatia
      • 5.6.7.1. Key country dynamics
      • 5.6.7.2. Regulatory framework
      • 5.6.7.3. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.8. Poland
      • 5.6.8.1. Key country dynamics
      • 5.6.8.2. Regulatory framework
      • 5.6.8.3. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.9. Netherlands
      • 5.6.9.1. Key country dynamics
      • 5.6.9.2. Regulatory framework
      • 5.6.9.3. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Asia Pacific
    • 5.7.1. Japan
      • 5.7.1.1. Key country dynamics
      • 5.7.1.2. Regulatory framework
      • 5.7.1.3. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.2. Australia
      • 5.7.2.1. Key country dynamics
      • 5.7.2.2. Regulatory framework
      • 5.7.2.3. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.3. South Korea
      • 5.7.3.1. Key country dynamics
      • 5.7.3.2. Regulatory framework
      • 5.7.3.3. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.4. New Zealand
      • 5.7.4.1. Key country dynamics
      • 5.7.4.2. Regulatory framework
      • 5.7.4.3. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Latin America
    • 5.8.1. Brazil
      • 5.8.1.1. Key country dynamics
      • 5.8.1.2. Regulatory framework
      • 5.8.1.3. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.2. Mexico
      • 5.8.2.1. Key country dynamics
      • 5.8.2.2. Regulatory framework
      • 5.8.2.3. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.3. Argentina
      • 5.8.3.1. Key country dynamics
      • 5.8.3.2. Regulatory framework
      • 5.8.3.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.4. Colombia
      • 5.8.4.1. Key country dynamics
      • 5.8.4.2. Regulatory framework
      • 5.8.4.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.5. Uruguay
      • 5.8.5.1. Key country dynamics
      • 5.8.5.2. Regulatory framework
      • 5.8.5.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.6. Chile
      • 5.8.6.1. Key country dynamics
      • 5.8.6.2. Regulatory framework
      • 5.8.6.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.7. Peru
      • 5.8.7.1. Key country dynamics
      • 5.8.7.2. Regulatory framework
      • 5.8.7.3. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. MEA
    • 5.9.1. Israel
      • 5.9.1.1. Key country dynamics
      • 5.9.1.2. Regulatory framework
      • 5.9.1.3. South Africa market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. Jazz Pharmaceuticals, Inc.
      • 6.3.1.1. Company overview
      • 6.3.1.2. Financial performance
      • 6.3.1.3. Product benchmarking
      • 6.3.1.4. Strategic initiatives
    • 6.3.2. AbbVie, Inc.
      • 6.3.2.1. Company overview
      • 6.3.2.2. Financial performance
      • 6.3.2.3. Product benchmarking
      • 6.3.2.4. Strategic initiatives
    • 6.3.3. Insys Therapeutics, Inc.
      • 6.3.3.1. Company overview
      • 6.3.3.2. Financial performance
      • 6.3.3.3. Product benchmarking
      • 6.3.3.4. Strategic initiatives
    • 6.3.4. Bausch Health Companies, Inc.
      • 6.3.4.1. Company overview
      • 6.3.4.2. Financial performance
      • 6.3.4.3. Product benchmarking
      • 6.3.4.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America cannabis pharmaceuticals market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 4 U.S. cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 5 Canada cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 6 Europe cannabis pharmaceuticals market, by region, 2018 - 2030 (USD Million)
  • Table 7 Europe cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 8 Germany cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 9 UK cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 10 France cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 11 Italy cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 12 Switzerland cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 13 Czech Republic cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 14 Croatia cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 15 Poland cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 16 Netherland cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific cannabis pharmaceuticals market, by region, 2018 - 2030 (USD Million)
  • Table 18 Asia Pacific cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 19 Japan cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 20 South Korea cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 21 Australia cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 22 New Zealand cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 23 Latin America cannabis pharmaceuticals market, by region, 2018 - 2030 (USD Million)
  • Table 24 Latin America cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 25 Brazil cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 26 Mexico cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 27 Argentina cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 28 Colombia cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 29 Uruguay cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 30 Chile cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 31 Peru cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 32 MEA cannabis pharmaceuticals market, by region, 2018 - 2030 (USD Million)
  • Table 33 MEA cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 34 Israel cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Cannabis pharmaceuticals market: market outlook
  • Fig. 9 Cannabis pharmaceuticals competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Cannabis pharmaceuticals market driver impact
  • Fig. 13 Cannabis pharmaceuticals market restraint impact
  • Fig. 14 Cannabis pharmaceuticals market: Brand type movement analysis
  • Fig. 15 Cannabis pharmaceuticals market: Brand type outlook and key takeaways
  • Fig. 16 Sativex market estimates and forecast, 2018 - 2030
  • Fig. 17 Epidiolex market estimates and forecast, 2018 - 2030
  • Fig. 18 Other brands market estimates and forecast, 2018 - 2030
  • Fig. 19 Global cannabis pharmaceuticals market: Regional movement analysis
  • Fig. 20 Global cannabis pharmaceuticals market: Regional outlook and key takeaways
  • Fig. 21 North America, by country
  • Fig. 22 North America market estimates and forecasts, 2018 - 2030
  • Fig. 23 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 24 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 25 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 26 UK market estimates and forecasts, 2018 - 2030
  • Fig. 27 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 28 France market estimates and forecasts, 2018 - 2030
  • Fig. 29 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 30 Poland market estimates and forecasts, 2018 - 2030
  • Fig. 31 Croatia market estimates and forecasts, 2018 - 2030
  • Fig. 32 Czech Republic market estimates and forecasts, 2018 - 2030
  • Fig. 33 Switzerland market estimates and forecasts, 2018 - 2030
  • Fig. 34 Netherland market estimates and forecasts, 2018 - 2030
  • Fig. 35 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 36 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 37 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 38 New Zealand market estimates and forecasts, 2018 - 2030
  • Fig. 39 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 40 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 41 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 42 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 43 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 44 Colombia market estimates and forecasts, 2018 - 2030
  • Fig. 45 Uruguay market estimates and forecasts, 2018 - 2030
  • Fig. 46 Chile market estimates and forecasts, 2018 - 2030
  • Fig. 47 Peru market estimates and forecasts, 2018 - 2030
  • Fig. 48 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 49 Israel market estimates and forecasts, 2018 - 2030